Lonza gains experienced scientific adviser

Company: Lonza

Professor Jonathan Knowles has joined Lonza Group in Switzerland as a part-time scientific adviser.

Professor Jonathan Knowles has joined Lonza Group in Switzerland as a part-time scientific adviser. In this role Knowles will be mainly supporting the LIFT (Lonza Innovation for Future Technologies) initiative, which aims to deliver long-term technology breakthroughs and new business platforms across all Lonza divisions. Knowles is a former member of the Roche executive committee and head of group research.

You may also like

Research & Development

The IND advantage: why early derisking is a strategic imperative for complex biologics

As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Research & Development

Stipple Bio enters into multi-target license agreement with Lonza to advance precision oncology ADC therapies

Stipple Bio’s Pointillist Platform identifies tumour-specific cell surface epitopes that, when combined with Lonza’s clinically validated ADC platform, may enable first-in-class and best-in-class ADC oncology medicines such as STP-100
Research & Development

Lonza advances integrated DNA‑to‑IND programmes with acceleration, derisking and innovation

New GS Ori‑Go vector technology supports titers higher than 11 g/L and reliable bulk pool stability, enabling more predictable material generation and shortened cell line development timelines
Manufacturing

Lonza and Oxford Nanopore launch direct RNA sequencing solution for GMP mRNA quality control

New nanopore sequencing and machine learning workflow simplifies multi-attribute QC testing for mRNA therapeutics
Manufacturing

Lonza expands AAV offering with Xcite AAV stable Producer Cell Line platform to idustrialise Viral Vector Manufacturing

New technology demonstrates superior performance versus transient transfection in clinically relevant customer gene of interest and engineered capsid, enabling scalable and cost-effective AAV manufacturing. Launch reflects Lonza’s deep expertise in cell line development, viral vector manufacturing, and platform industrialisation built over decades of supporting complex biologics
Manufacturing

Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target

BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target
Manufacturing

Swiss Rockets collaborates with Lonza to advance Torqur’s oncology drug candidate bimiralisib into late-stage clinical development

Lonza to provide cGMP manufacturing and technical support to advance bimiralisib into late-stage clinical development
Subscribe now